uterine cancer
Aprea Therapeutics Begins Phase I Trial of WEE1 Inhibitor in Biomarker-Defined Solid Tumors
The firm is evaluating its WEE1 inhibitor APR-1051 in advanced solid tumors, including colorectal and uterine cancer.
Debiopharm Begins Phase I Expansion Study of WEE1 Inhibitor
The expansion portion of the trial will include ovarian cancer patients with cyclin E1-driven tumors and biomarker-selected solid tumors.
HighField Biopharmaceuticals to Study Immunoliposome in HER2-Low, -Positive Solid Tumors
The FDA cleared HighField's IND for a Phase I trial evaluating HF158K1, which the firm says could have advantages over HER2-targeting antibody-drug conjugates.
Genetic Testing Challenges in Oncology: Myotonic Dystrophy Signs Missed in Uterine Cancer Patient
No physician had noticed that this endometrial cancer patient had a strong family history and physical signs of myotonic dystrophy, which is known to increase the risk of uterine cancers.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.